Early inhibition of reprogramming effects of Ang-2 and VEGF on the brain perivascular pre-metastatic niche by combined AMG 386/aflibercept therapy is beneficial in preclinical xenograft models of breast carcinoma and melanoma BM, demonstrating a substantial reduction of the brain metastatic tumor load. This evidence concerns the gene VEGFA and breast carcinoma.